<DOC>
	<DOCNO>NCT00426530</DOCNO>
	<brief_summary>This study look different dose level regimens everolimus combined weekly trastuzumab vinorelbine therapy patient HER-2 overexpressing metastatic breast cancer .</brief_summary>
	<brief_title>Safety Everolimus Combination Therapy , Patients With HER2-overexpressing Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : Female male patient ≥18 year WHO performance status ≤ 1 HER2 overexpressing metastatic breast cancer cell confirm histology Progressive disease prior trastuzumab alone/or combination anticancer agent , relapse time completion therapy Patients neurologically stable adequate bone marrow , liver renal function Exclusion criterion : Patients receive endocrine therapy breast cancer ≤ 2 week prior study treatment start Patients currently receive chemotherapy , immunotherapy radiotherapy receive ≤ 4 week prior study treatment start patient receive lapatinib ≤ 2 week prior study treatment start Patients previously receive vinorelbine mTOR inhibitor Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HER2-overexpressing metastatic breast cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Cancer breast</keyword>
	<keyword>Human mammary carcinoma</keyword>
	<keyword>HER-2</keyword>
	<keyword>metastatic</keyword>
	<keyword>everolimus</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>vinorelbine</keyword>
</DOC>